For most people, a piece of gum is a fleeting moment of flavor. For Vishar Yaghoubian, it is a vehicle for a clinical intervention. The University of Toronto alum and her co-founder, PhD candidate Brian Webb, are building Toothpod on a simple, if ambitious, premise: that a chewable tablet can deliver measurable, research-backed oral hygiene benefits when a toothbrush is out of reach [University of Toronto]. It is a bet that oral care, a field dominated by decades-old mechanical tools, is ready for a bioactive, portable supplement.
Toothpod’s product is a mint-flavored chewable tablet, sold in 20-packs direct to consumers. The company positions it not as a replacement for brushing, but as a functional supplement for the moments in between,after a lunch meeting, during travel, or post-coffee [YouTube]. The active ingredients, which the company describes as all-natural, are formulated to offer anti-microbial, anti-inflammatory, and enamel-remineralizing properties [entrepreneurs.utoronto.ca]. For Yaghoubian, who has a background in dental training, the goal is to move beyond cavity prevention and into measurable gum health [dew.life]. The company has secured $850,000 in funding and an additional $450,000 in grants, according to public reports, backing its early-stage research and commercial push [Startup Story].
The Clinical Wedge
The core of Toothpod’s differentiation is its claim to be “the world’s first research-backed remineralizing chewing gum” [f4.fund]. This is more than marketing. The startup has partnered with the Harvard School of Dental Medicine to conduct a clinical trial, a significant credential for a pre-seed company in the consumer health space [The Globe and Mail]. While detailed results are not yet public, the study reportedly involves 60 healthy periodontal patients in the U.S., measuring impacts on oral microbiota and enamel health [YouTube]. This scientific validation is the wedge Toothpod hopes will separate it from conventional sugar-free gums and even newer competitors like Bite or Huppy, which focus more on natural ingredients than on clinical outcomes.
For a direct-to-consumer product making health claims, this regulatory and scientific groundwork is not optional; it is essential. The company is navigating its product as a supplement, a category with its own set of FDA rules. The clinical partnership provides a layer of credibility that pure marketing cannot, and it signals a path toward more serious conversations with dental professionals and large distributors.
The Founders and Early Traction
The team is a blend of clinical aspiration and academic rigor. CEO Vishar Yaghoubian is an emerging figure in Toronto’s startup ecosystem, having won over $200,000 in prizes from more than 25 competitions [goodmanstech.ca]. She serves as an Entrepreneur in Residence at NEXT Canada and has been featured in Canadian business press for her rapid ascent [theorg.com, The Globe and Mail]. Co-founder Brian Webb brings a biomedical research perspective from his PhD candidacy at the University of Toronto [Brian Webb - U Corp/Toothpod | LinkedIn].
Their early backers include a mix of Canadian institutional and angel investors, such as the F4 Fund, Archangel Network of Funds, LOI Venture, Elevate, and angels Michael Cloutier and Michele Romanow [F4 Fund, Michael Cloutier - EVERSANA | LinkedIn]. This support has funded not just product development but also the crucial early-stage clinical work.
| Founder | Role | Key Background |
|---|---|---|
| Vishar Yaghoubian | Co-Founder & CEO | Dental training; award-winning U of T entrepreneur; Entrepreneur in Residence, NEXT Canada [dew.life, goodmanstech.ca, theorg.com] |
| Brian Webb | Co-Founder | PhD candidate in biomedical engineering, University of Toronto [Brian Webb - U Corp/Toothpod |
The Path Beyond DTC
Toothpod’s current direct-to-consumer website is a starting point, but the company’s announced strategy reveals a more ambitious channel plan. It has secured an agreement to roll out its product in a major Dental Service Organization (DSO) with 400 clinics across the United States [The Globe and Mail]. This is a pivotal move. Success in a clinical setting would represent a powerful endorsement, transforming the chewable from a consumer novelty into a recommended adjunct to care. It also opens a more predictable, high-volume B2B revenue stream alongside DTC sales.
The company appears to be thinking of its chewable as a potential platform. In interviews, Yaghoubian has suggested the delivery mechanism could evolve beyond gum, pointing to a broader vision for delivering active oral-care ingredients in convenient, non-brush formats [YouTube]. This platform thinking is common in biotech but rare in oral care, a market often defined by incremental innovation on the brush and paste.
The Risks on the Shelf
The bet is clear, but the path is lined with challenges familiar to any company blending clinical science with consumer packaged goods.
- Clinical proof. The partnership with Harvard is a strong signal, but the burden of proof remains. Until peer-reviewed data is published, the specific efficacy claims,remineralization, anti-inflammatory effects,rest on the credibility of the institution rather than public evidence. The company must successfully translate its study into clear, compliant marketing claims.
- Category creation. Toothpod is not just selling gum; it is asking consumers to rethink a daily habit and pay a premium for a clinical benefit they cannot see. Educating the market and justifying a price point above conventional gum will require consistent, sophisticated messaging.
- Competitive response. The oral care aisle is crowded and well-funded. Established players like Colgate or Procter & Gamble could quickly replicate a bioactive gum format if the category gains traction, leveraging their massive distribution and R&D budgets.
The company’s most plausible answer to these risks is its dual-track strategy. By pursuing both the clinical channel (400 DSO clinics) and a direct-to-consumer presence, it aims to build credibility from the top down while driving awareness from the bottom up. The DSO rollout, if executed well, provides the validation needed to overcome consumer skepticism.
The Next Twelve Months
The coming year will be decisive for Toothpod. The key milestones are the execution of its DSO rollout and the publication of initial data from its Harvard clinical trial. Success in the dental clinics would prove its B2B model and establish professional endorsement. Concurrently, the company will likely need to raise a seed round to scale manufacturing, support broader marketing, and potentially fund additional clinical studies to expand its claims.
The ultimate patient population here is broad: anyone susceptible to cavities or gum inflammation between brushes. But the initial beachhead is likely those already motivated about oral health,perhaps individuals with a history of cavities, orthodontic patients, or frequent travelers. The standard of care today for these moments is, effectively, nothing. A quick rinse with water or a piece of sugar-free gum might offer temporary freshness, but neither is designed to actively combat bacteria or support remineralization. Toothpod is betting that there is a meaningful gap between the twice-daily brush and total neglect, a gap wide enough for a clinically formulated chewable to build a business.
Sources
- [University of Toronto] U of T oral health startup launches dental 'smart' gum | https://www.utoronto.ca/news/u-t-oral-health-startup-launches-dental-smart-gum-globe-and-mail-betakit
- [YouTube] Podcast interview with Vishar Yaghoubian | https://www.youtube.com/watch?v=vOD1X27V4mg
- [entrepreneurs.utoronto.ca] Toothpod startup profile | https://entrepreneurs.utoronto.ca/startup/toothpod/
- [dew.life] Finding My Path in Dentistry: The Story Behind Toothpod | https://dew.life/2025/12/finding-my-path-in-dentistry-the-story-behind-toothpod-and-what-dew-life-means-to-me/
- [Startup Story] U of T Oral Health Startup Launches Dental 'Smart' Gum | https://startupstorymedia.com/u-of-t-oral-health-startup-launches-dental-smart-gum/
- [f4.fund] ToothPod, Healthcare & Digital Health | https://f4.fund/startups/toothpod
- [The Globe and Mail] With launch of Toothpod, U of T startup star shifts from winning awards to fighting plaque | https://www.theglobeandmail.com/business/article-vishar-yaghoubian-toothpod-dental-startup-entrepreneur-medical-tech/
- [goodmanstech.ca] Toothpod Launches an Innovative, Chewable Dental Hygiene Tablet | https://www.goodmans.ca/insights/post/goodmans-tech-blog/toothpod-launches-an-innovative--chewable-dental-hygiene-tablet
- [theorg.com] Vishar Yaghoubian profile | https://theorg.com/people/vishar-yaghoubian
- [Brian Webb - U Corp/Toothpod | LinkedIn] Profile | https://www.linkedin.com/in/brian-webb-ucorp
- [Michael Cloutier - EVERSANA | LinkedIn] Profile noting investment | https://www.linkedin.com/in/mikecloutier/